Advocacy Highlights 2023

USPSTF

Standing in the Way of Pediatric Screening

No Comments

The Family Heart Foundation’s Back and Forth with the United States Preventive Services Task Force

Since 2011 the American Academy of Pediatrics (AAP) and the National Institutes of Health (NIH) have recommended screening children at the age of 2 if they have a family history of premature vascular … Read More →


Research

2023 Family Heart Foundation Research Highlights

No Comments

When it comes to the diagnosis and treatment of familial hypercholesterolemia (FH) and elevated lipoprotein(a), or Lp(a), there are still so many unanswered questions.
What we have learned from our research is impacting peoples’ lives right now. We are using artificial intelligence to address the … Read More →


American Heart Association 2023

Highlights from the American Heart Association’s Annual Scientific Sessions

No Comments

The American Heart Association’s (AHA) 2023 Scientific Session was held in Philadelphia from November 11-13. This is one of the premier scientific meetings of the year with over 10,000 clinicians and researchers in attendance. Sessions focused on the latest research and insights to improve cardiovascular … Read More →


Family Heart Foundation Congressional Briefing

Shining a Light on LDL Cholesterol Management in America

No Comments

September is National Cholesterol Education Month, and that makes it the perfect time to shine a light on cholesterol management in America. Family Heart Foundation research shows that 70% of Americans at high-risk for cardiovascular disease never get their LDL (“bad”) cholesterol to recommended … Read More →


Public Comment for Screening for Lipid Disorders in Children and Adolescents

Family Heart Foundation Public Comment for Screening for Lipid Disorders in Children and Adolescents

No Comments

A Response to the US Preventive Service Task Force

On January 24, 2023, the US Preventive Services Task Force (USPSTF) released their draft recommendation based on evidence of the benefits and harms of screening for lipid disorders, including familial hypercholesterolemia (FH), in children and … Read More →


Highlights from AHA 2022

FDA Approves Inclisiran

A Global Call to Action for FH